Mission statement · Company scope
“Our mission is to develop novel proprietary mebufotenin therapies to induce ultra-rapid and durable remissions in patients with psychiatric and neurological disorders.”
In use2026 – now1 sighting
First seenMar 2026Added
Last seenMar 2026Latest observation
Date created—Not published by the organization
Record
- Kind
- Mission
- Scope
- Company
- Style
- Product offering (primary) · Innovation
- Leads with
- Product
- Best for
- Climate & health
- Formula
- We make [product] for [who]
- Tone
- Plain
- Length
- 22 words · reading grade 19.5
- Review status
- unreviewed · classifier rules-v0
- Quality score
- 0.74
- Record
- st_9053beafe3e27225
- Classification confidence
- 0.59
Sources1 sighting
SEC
SEC EDGAR filingsObserved 2026-03-05 · sec_sentence · 20-F · accession 0001140361-26-007986
View filing ↗0 to compareCompare